Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study

“…Randomized phase III trials investigating combinations of targeted agents with docetaxel versus docetaxel alone as second-line therapy for advanced NSCLC showed improved OS with the combination regimens 32,33 but not improvements or prolonged time to deterioration in PROs. 18,19 CheckMate 017 is the first trial showing symptom and health status improvements and prolongation of time to deterioration with nivolumab versus with docetaxel. Similar proportions of patients exhibited diseaserelated symptom improvement by week 12, as measured by the LCSS, with nivolumab versus with docetaxel.…”

“…11,12 Few studies have reported on HRQoL in the second-line NSCLC setting, and none has evaluated patients with the squamous histologic type specifically. [13][14][15][16][17][18][19] In CheckMate 017, HRQoL was analyzed by using the validated, patient-reported Lung Cancer Symptom Scale (LCSS) and the European Quality of Life Five Dimensions (EQ-5D) questionnaires. We report the impact of nivolumab and docetaxel on HRQoL and symptoms in patients with squamous NSCLC.…”

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

“…Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0 [28]. Quality of life (QoL) was assessed at baseline, the end of each cycle, and at the 30-day follow-up using the Lung Cancer Symptom Scale (LCSS) [25,29,30].…”

Anti-Angiogenics: Their Value in Lung Cancer Therapy

“…Typical grade 3 VEGF-related AEs (bleeding, hypertension, proteinuria) were reported for 2% of the patients for both treatments. Both trials reported no detrimental effect on quality of life by addition of AAT to docetexal [23,27,51,52]. The response to anti-angiogenic drugs is very heterogeneous, and the different efficacy in sq versus non-sq carcinoma patients or in patients with activating EGFR mutations suggests that patient selection is indeed crucial.…”